Ultragenyx Pharmaceutical (RARE) PT Set at $70.00 by Raymond James

Ultragenyx Pharmaceutical (NASDAQ:RARE) has been assigned a $70.00 price target by Raymond James in a research note issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Raymond James’ price objective suggests a potential upside of 43.97% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Wedbush raised their target price on Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, August 6th. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 29th. Morgan Stanley restated an “equal weight” rating and issued a $92.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, September 10th. Piper Jaffray Companies lowered their target price on Ultragenyx Pharmaceutical to $70.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, ValuEngine upgraded Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $83.83.

Shares of Ultragenyx Pharmaceutical stock opened at $48.62 on Friday. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $90.98.



Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. The business had revenue of $12.79 million for the quarter, compared to analysts’ expectations of $5.63 million. During the same period in the prior year, the firm earned ($1.72) EPS. On average, research analysts anticipate that Ultragenyx Pharmaceutical will post -4.38 earnings per share for the current year.

In other news, EVP Karah Herdman Parschauer sold 5,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $78.53, for a total transaction of $392,650.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William Aliski sold 3,750 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $76.66, for a total value of $287,475.00. Following the transaction, the director now owns 72,610 shares in the company, valued at $5,566,282.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,000 shares of company stock worth $2,700,774. 8.40% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Ultragenyx Pharmaceutical by 3.8% during the 2nd quarter. BlackRock Inc. now owns 4,389,350 shares of the biopharmaceutical company’s stock valued at $337,408,000 after purchasing an additional 158,723 shares during the period. Federated Investors Inc. PA increased its position in shares of Ultragenyx Pharmaceutical by 18.2% during the 2nd quarter. Federated Investors Inc. PA now owns 1,417,551 shares of the biopharmaceutical company’s stock valued at $108,967,000 after purchasing an additional 218,060 shares during the period. First Trust Advisors LP increased its position in shares of Ultragenyx Pharmaceutical by 29.3% during the 3rd quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock valued at $96,453,000 after purchasing an additional 285,961 shares during the period. Northern Trust Corp increased its position in shares of Ultragenyx Pharmaceutical by 6.7% during the 2nd quarter. Northern Trust Corp now owns 554,092 shares of the biopharmaceutical company’s stock valued at $42,594,000 after purchasing an additional 34,942 shares during the period. Finally, Voya Investment Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 2,221.4% during the 2nd quarter. Voya Investment Management LLC now owns 426,788 shares of the biopharmaceutical company’s stock valued at $32,807,000 after purchasing an additional 408,403 shares during the period. Institutional investors own 96.11% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Further Reading: Float

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply